These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11745403)

  • 41. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haemophilus influenzae type b conjugate vaccines.
    Kelly DF; Moxon ER; Pollard AJ
    Immunology; 2004 Oct; 113(2):163-74. PubMed ID: 15379976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys.
    Vella PP; Ellis RW
    Pediatr Res; 1991 Jan; 29(1):10-3. PubMed ID: 2000253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
    Hale SF; Camaione L; Lomaestro BM
    Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
    Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological characterization of conjugated Haemophilus influenzae type b vaccine failure in infants.
    Breukels MA; Spanjaard L; Sanders LA; Rijkers GT
    Clin Infect Dis; 2001 Jun; 32(12):1700-5. PubMed ID: 11360210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages.
    Ambrosino DM; Bolon D; Collard H; Van Etten R; Kanchana MV; Finberg RW
    J Immunol; 1992 Dec; 149(12):3978-83. PubMed ID: 1460286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.
    Eskola J; Ward J; Dagan R; Goldblatt D; Zepp F; Siegrist CA
    Lancet; 1999 Dec; 354(9195):2063-8. PubMed ID: 10636384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
    Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C; Poolman J; Boutriau D
    Vaccine; 2007 Dec; 25(51):8487-99. PubMed ID: 17996996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.
    Fernández-Santana V; Cardoso F; Rodriguez A; Carmenate T; Peña L; Valdés Y; Hardy E; Mawas F; Heynngnezz L; Rodríguez MC; Figueroa I; Chang J; Toledo ME; Musacchio A; Hernández I; Izquierdo M; Cosme K; Roy R; Verez-Bencomo V
    Infect Immun; 2004 Dec; 72(12):7115-23. PubMed ID: 15557635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
    Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH
    Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemophilus influenzae type B conjugate vaccines.
    Force RW; Lugo RA; Nahata MC
    Ann Pharmacother; 1992 Nov; 26(11):1429-40. PubMed ID: 1477450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
    Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
    Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycoconjugate vaccines: some observations on carrier and production methods.
    MacCalman TE; Phillips-Jones MK; Harding SE
    Biotechnol Genet Eng Rev; 2019 Oct; 35(2):93-125. PubMed ID: 32048549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines.
    Ravenscroft N; Averani G; Bartoloni A; Berti S; Bigio M; Carinci V; Costantino P; D'Ascenzi S; Giannozzi A; Norelli F; Pennatini C; Proietti D; Ceccarini C; Cescutti P
    Vaccine; 1999 Jul; 17(22):2802-16. PubMed ID: 10438050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a bivalent conjugate vaccine candidate against rotaviral diarrhea and tuberculosis using polysaccharide from Mycobacterium tuberculosis conjugated to ΔVP8* protein from rotavirus.
    Park WJ; Yoon YK; Kim Y; Park JS; Pansuriya R; Cho SN; Seok YJ; Ganapathy R
    Vaccine; 2021 Oct; 39(45):6644-6652. PubMed ID: 34642087
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.
    de Velasco EA; Merkus D; Anderton S; Verheul AF; Lizzio EF; Van der Zee R; Van Eden W; Hoffman T; Verhoef J; Snippe H
    Infect Immun; 1995 Mar; 63(3):961-8. PubMed ID: 7532630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.